| 293.009 1.079 (0.37%) | 01-14 13:03 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 345.13 |
1-year : | 403.11 |
| Resists | First : | 295.48 |
Second : | 345.13 |
| Pivot price | 257.28 |
|||
| Supports | First : | 255.95 |
Second : | 231.5 |
| MAs | MA(5) : | 273.38 |
MA(20) : | 252.86 |
| MA(100) : | 199.88 |
MA(250) : | 172.89 |
|
| MACD | MACD : | 13.4 |
Signal : | 10.1 |
| %K %D | K(14,3) : | 96 |
D(3) : | 88 |
| RSI | RSI(14): 82.6 |
|||
| 52-week | High : | 295.48 | Low : | 122.8 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ KRYS ] has closed above the upper band by 7.8%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 129.5% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 292.92 - 293.94 | 293.94 - 294.88 |
| Low: | 263.91 - 265.14 | 265.14 - 266.26 |
| Close: | 289.83 - 291.68 | 291.68 - 293.37 |
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Wed, 14 Jan 2026
5 Stocks With Recent Price Strength to Maximize Your Gains - TradingView — Track All Markets
Mon, 12 Jan 2026
KRYS Stock: Citigroup Raises Price Target to $336, Maintains Buy - GuruFocus
Mon, 12 Jan 2026
KRYS Reports Preliminary Results for 2025, Outlines 2026 Objectives - Prime Publishers, Inc.
Mon, 12 Jan 2026
Krystal Biotech outlines rare disease growth strategy update - TipRanks
Mon, 12 Jan 2026
Krystal Biotech, Inc. (KRYS) Stock Analysis: Navigating A Promising 4.05% Potential Upside - DirectorsTalk Interviews
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 29 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 11.6 (%) |
| Held by Institutions | 99.3 (%) |
| Shares Short | 2,720 (K) |
| Shares Short P.Month | 2,870 (K) |
| EPS | 6.67 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 39.25 |
| Profit Margin | 53.2 % |
| Operating Margin | 42.3 % |
| Return on Assets (ttm) | 8.9 % |
| Return on Equity (ttm) | 19.6 % |
| Qtrly Rev. Growth | 16.6 % |
| Gross Profit (p.s.) | 12.12 |
| Sales Per Share | 12.86 |
| EBITDA (p.s.) | 5.5 |
| Qtrly Earnings Growth | 192.3 % |
| Operating Cash Flow | 176 (M) |
| Levered Free Cash Flow | 76 (M) |
| PE Ratio | 43.86 |
| PEG Ratio | 0 |
| Price to Book value | 7.45 |
| Price to Sales | 22.73 |
| Price to Cash Flow | 48.14 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|